Uribe 1979.

Methods	Cross‐over trial.
Participants	Type of hepatic encephalopathy: chronic hepatic encephalopathy. Type of liver disease: cirrhosis due to alcohol (63%) or viral hepatitis (37%). Mean age: not reported (range 45 to 78 years). Proportion of men: 63%.
Interventions	Dopamine agent: bromocriptine 15 mg/d. Control: placebo. Treatment duration: two weeks.
Outcomes	Hepatic encephalopathy, mortality, and adverse events.
Notes	Health economics: not assessed.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number table.
Allocation concealment (selection bias)	Low risk	Central administration of blinded drug containers.
Blinding (performance bias and detection bias) All outcomes	Low risk	Double‐blind placebo‐controlled with additional blinded data analyses.
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for.
Selective reporting (reporting bias)	Low risk	Clinically relevant outcome measures defined and reported.
Sample size calculations	Unclear risk	Not reported.